Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

Core Viewpoint - Gossamer Bio reported a quarterly loss of $0.17 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.18, marking an earnings surprise of +5.56% [1] - The company has consistently surpassed consensus EPS estimates over the last four quarters [2] Financial Performance - Gossamer Bio posted revenues of $11.49 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 155.88%, compared to revenues of $95.84 million a year ago [2] - The company has also topped consensus revenue estimates four times in the last four quarters [2] Stock Performance - Gossamer Bio shares have increased approximately 139.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] Future Outlook - The company's earnings outlook will be crucial for investors, particularly in understanding how current consensus earnings expectations may evolve [4] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $5.78 million, and for the current fiscal year, it is -$0.69 on revenues of $28.57 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Gossamer Bio belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges ahead [8]